Cell-Free DNA Potential in Guiding Therapies and Q&A – Module 5

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (5 of 5 Modules)

This activity provides an overview of recent data supporting the potential utility of circulating tumor DNA to predict risk and inform personalized therapeutic decision making for patients with lymphoma.

1.00 CE Credit(s)

Expires: March 12, 2024

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Examine the potential utility of circulating tumor DNA for risk prediction and individualizing therapy for diffuse large B-cell lymphoma (DLBCL)

Activity Faculty

Mark Roschewski, MD

Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Provider Statement

This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Supporter Statement

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.